ACOG Alpha Cognition Inc

$ACOG The CONVERGE study demonstrates high real-world tolerability with an 80% target dose achievement rate among long-term care patients. This validates ZUNVEYL’s GI-friendly prodrug mechanism, providing crucial commercial leverage for broader physician adoption and PBM coverage.

$ACOG Management is having a virtual meeting with B Riley on Sept. 29. I think this will be a very positive corporate update in my opinion.

$ACOG Amidst another quarter of double digit growth. $14-$20 by EOY. Likely a BO candidate between $30-$50 2027. Higher if it lasts until 2028.

$ACOG One of the most important points to consider relative to the data seen in the Converge study is that it helps patients get off of and/or reduce their "multi drug cocktail".

$ACOG FYI - There is a new major investor here - MANCHESTER MANAGEMENT CO LLC loaded approx. 52% more shrs to an ownership of 7.4%!!

$ACOG Crazy that ACOG is still this unknown. In a year this will be a billion dollar company and that just will be the start.

$ACOG It is significant that Opaleye bought more shares recently. My guess is that they know that the launch is going well.

$ACOG announced inducement stock options for a new employee under Nasdaq Rule 5635(c)(4).

$ACOG Don't worry guys, I recently sold some shares so ACOG will probably squeeze in a couple of days now :D

$ACOG problem here is the company dont announce anything, no study complete, no ex us approval, no top line results.

$ACOG https://www.businesswire.com/news/home/20260909061312/en/Alpha-Cognition-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4 -Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4— *Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on September 8, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 25,000 shares of common stock to a new non-executive employee under the Company’s 2026 Inducement Grant Plan.*